MarketLens

Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise

2 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Agree Realty (ADC) a Buy After Its Recent Pullback

5 months ago

Is Lemonade's AI-Driven Model Finally Delivering on its Promise

3 months ago

Datadog's AI Promise Can't Outrun Its Valuation Reality

1 months ago

Unusual Machines: A High-Stakes Bet on the U.S. Drone Boom's Promise

1 months ago

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success

AstraZeneca halted a phase III NSCLC study of volrustomig after data showed the regimen is unlikely to meet key survival goals, while other lung cancer trials showed positive results.

AZN

Stock News•1 week ago

ADC Therapeutics Q2 Earnings Call Highlights

ADC Therapeutics' ZYNLONTA generated $18.6M in Q2 2026 net product revenue, up from $18.1M a year earlier, as executives said commercial performance stayed broadly consistent with recent quarters.

ADC

Stock News•3 weeks ago

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

Allogene Therapeutics received FDA RMAT and Fast Track designations for cema-cel in first-line LBCL consolidation, after ALPHA3 trial data showed 58.3% MRD clearance and a 97.7% median ctDNA reduction...

ALLO

Stock News•1 months ago

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

Helus Pharma's valuation (~$269M EV) under-credits HLP003's probability-weighted value, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds. The pivotal APPROACH readout in Q4 2026 sets up a...

HLP